Humacyte Launches Symvess For Extremity Vascular Trauma
26/2 20:28
(RTTNews) - Humacyte, Inc. (HUMA) has launched Symvess, a bioengineered vascular conduit for adults needing urgent revascularization due to extremity arterial injury when autologous vein grafts aren't feasible. The FDA fully approved Symvess on December 19, 2024, and has now auth...